Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Exchange Rate Effect (2019 - 2025)

Historic Exchange Rate Effect for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $2.8 million.

  • Legend Biotech's Exchange Rate Effect rose 44141.22% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 28947.69%. This contributed to the annual value of -$2.1 million for FY2024, which is 40571.85% down from last year.
  • As of Q3 2025, Legend Biotech's Exchange Rate Effect stood at $2.8 million, which was up 44141.22% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Exchange Rate Effect registered a high of $4.4 million during Q2 2025, and its lowest value of -$2.4 million during Q1 2023.
  • Moreover, its 5-year median value for Exchange Rate Effect was $10000.0 (2022), whereas its average is $252578.9.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first crashed by 2364000.0% in 2023, then skyrocketed by 4924444.44% in 2025.
  • Legend Biotech's Exchange Rate Effect (Quarter) stood at $78000.0 in 2021, then crashed by 1521.79% to -$1.1 million in 2022, then surged by 231.11% to $1.5 million in 2023, then plummeted by 256.46% to -$2.3 million in 2024, then soared by 224.7% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $4.4 million for Q2 2025, and $1.4 million during Q1 2025.